Testicular cancer · 2 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Etoposide monotherapy Variant #01 | — | R 2 872 | 28d | — | — | — | — | — |
Carboplatin and Etoposide (CE) Variant #10 | — | R 2 265 | 21d | ~4.6 mo | ~10.6 mo | ~7 | ~R 15 853 PFS proxy · indirect | 17 |
2 of 2 regimens shown